我們已在上線！進一步了解

Omeros

OMER

市值 US$11.7億

16.20 USD

-2.59

13.78%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

16.25

+0.05

0.31%

1天

-13.78%

5天

-17.93%

1個月

-6.57%

3個月

75.7%

6個月

29.19%

今年迄今

-1.1%

1年

64.8%

5年

185.71%

10年

113.16%

關於： Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

員工： 175

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 37.5%

中性 56.3%

負面 6.3%

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Zacks Investment Research

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Investors Business Daily

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications.

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Q2 Earnings Call Highlights

Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.

Omeros Q2 Earnings Call Highlights

Zacks Investment Research

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros Corporation Reports Second Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.

Omeros Corporation Reports Second Quarter 2026 Financial Results

查看新聞排名

價格圖表採用Lightweight Charts™實作